Summary statistics - qualitative results

EQA round: IGIT2/26 - Immunopathology of GIT

Deadline: 16.10.2026

Setup: groups - M (measurement principle)

AV = assigned value
CVP = consensus of all participants
>>> ... expected result
> ... acceptable result
± ... result not assessed

N_{tot} = total number of the results
N_{rel} = relative number of the results

N_{eva} = number of the results assessed
N_{suc} = number of successful results
S_{rel} = relative success

Test / Sample / Group	AV		Frequency of the results N_{tot}	N_{rel} [%]	Result	Success N_{eva}	N_{suc}	S_{rel} [%]
Set 1								
(595) **anti-gliadin IgA (deamidated)**			77			77	77	100
Sample A1			77			77	77	100
(1) Fluorescent methods	CVP	>>>	1	1,3	Negative			
(2) EIA methods	CVP	>>>	49	64	Negative			
(5) LIA, ILMA	CVP	>>>	24	31	Negative			
(99) Another measurement principle	CVP	>>>	3	3,9	Negative			
Sample B1			77			77	77	100
(1) Fluorescent methods	CVP	>>>	1	1,3	Positive			
(2) EIA methods	CVP	>>>	49	64	Positive			
(5) LIA, ILMA	CVP	>>>	24	31	Positive			
(99) Another measurement principle	CVP	>>>	3	3,9	Positive			
(594) **anti-gliadin IgG (deamidated)**			77			77	77	100
Sample A1			77			77	77	100
(1) Fluorescent methods	CVP	>>>	1	1,3	Negative			
(2) EIA methods	CVP	>>>	49	64	Negative			
(5) LIA, ILMA	CVP	>>>	24	31	Negative			
(99) Another measurement principle	CVP	>>>	3	3,9	Negative			
Sample B1			77			77	77	100
(1) Fluorescent methods	CVP	>>>	1	1,3	Positive			
(2) EIA methods	CVP	>>>	49	64	Positive			
(5) LIA, ILMA	CVP	>>>	24	31	Positive			
(99) Another measurement principle	CVP	>>>	3	3,9	Positive			
Set 2								
(424) **anti-endomysium IgA**			69			69	69	100
Sample A2			69			69	69	100
(1) Fluorescent methods	CVP	>>>	68	99	Negative			
(2) EIA methods	CVP	>>>	1	1,4	Negative			
Sample B2			69			69	69	100
(1) Fluorescent methods	CVP	>>>	68	99	Positive			
(2) EIA methods	CVP	>>>	1	1,4	Positive			
(425) **anti-transglutaminase IgA**			86			86	86	100
Sample A2			86			86	86	100
(1) Fluorescent methods	CVP	>>>	1	1,2	Negative			
(2) EIA methods	CVP	>>>	57	66	Negative			
(5) LIA, ILMA	CVP	>>>	26	30	Negative			
(99) Another measurement principle	CVP	>>>	2	2,3	Negative			
Sample B2			86			86	86	100
(1) Fluorescent methods	CVP	>>>	1	1,2	Positive			
(2) EIA methods	CVP	>>>	57	66	Positive			
(5) LIA, ILMA	CVP	>>>	26	30	Positive			
(99) Another measurement principle	CVP	>>>	2	2,3	Positive			
Set 3								
(592) **anti-Saccharomyces cerevisiae IgA**			67			67	65	97
Sample A3			67			67	67	100
(1) Fluorescent methods	CVP	>>>	27	40	Positive			
(2) EIA methods	CVP	>>>	37	55	Positive			
(5) LIA, ILMA	CVP	>>>	2	3	Positive			
(99) Another measurement principle	CVP	>>>	1	1,5	Positive			
Sample B3			67			67	65	97
(1) Fluorescent methods	CVP	>>>	26	39	Negative			
			1	1,5	Positive			
(2) EIA methods	CVP	>>>	36	54	Negative			
			1	1,5	Positive			
(5) LIA, ILMA	CVP	>>>	2	3	Negative			
(99) Another measurement principle	CVP	>>>	1	1,5	Negative			
(593) **anti-Saccharomyces cerevisiae IgG**			58			0		
Sample A3			58			58	57	98
(1) Fluorescent methods	CVP	>>>	20	34	Positive			
(2) EIA methods			1	1,7	Negative			
	CVP	>>>	34	59	Positive			
(5) LIA, ILMA	CVP	>>>	2	3,4	Positive			
(99) Another measurement principle	CVP	>>>	1	1,7	Positive			

Summary statistics - qualitative results

EQA round: IGIT2/26 - Immunopathology of GIT

Deadline: 16.10.2026

Setup: groups - M (measurement principle)

Test / Sample / Group	AV	N_{tot}	N_{rel} [%]	Result	Success N_{eva}	Success N_{suc}	Success S_{rel} [%]
Sample B3		58			0		
(1) Fluorescent methods	±	17	29	Negative			
	±	3	5,2	Positive			
(2) EIA methods	±	24	41	Negative			
	±	4	6,9	Inconclusive result (borderline)			
	±	7	12	Positive			
(5) LIA, ILMA	±	1	1,7	Negative			
	±	1	1,7	Positive			
(99) Another measurement principle	±	1	1,7	Negative			